Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 9.86 0.00% 0.00
IRWD closed unchanged on Friday, July 10, 2020, on 34 percent of normal volume.
Earnings due: Jul 28
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical IRWD trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Fell Below 20 DMA Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Down 3 Days in a Row Weakness 0.00%
20 DMA Support Bullish -1.30%
Multiple of Ten Bearish Other -1.30%
50 DMA Resistance Bearish -3.00%
50 DMA Resistance Bearish -3.99%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Medical Specialties Cardiovascular Diseases Central Nervous System Disorders Gastroenterology Peptides European Union Gastrointestinal Diseases Irritable Bowel Syndrome Digestive Diseases Constipation Gastrointestinal Disorders Human Therapeutic Products Ironwood Pharmaceuticals

Is IRWD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.1
52 Week Low 7.91
Average Volume 2,180,476
200-Day Moving Average 10.92
50-Day Moving Average 10.28
20-Day Moving Average 9.94
10-Day Moving Average 10.10
Average True Range 0.45
ADX 8.01
+DI 20.27
-DI 21.98
Chandelier Exit (Long, 3 ATRs ) 9.56
Chandelier Exit (Short, 3 ATRs ) 10.28
Upper Bollinger Band 10.58
Lower Bollinger Band 9.30
Percent B (%b) 0.44
BandWidth 12.79
MACD Line -0.04
MACD Signal Line -0.05
MACD Histogram 0.0043
Fundamentals Value
Market Cap 1.47 Billion
Num Shares 150 Million
EPS -0.98
Price-to-Earnings (P/E) Ratio -10.06
Price-to-Sales 8.05
Price-to-Book 441.52
PEG Ratio -0.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.16
Resistance 3 (R3) 10.14 10.03 10.11
Resistance 2 (R2) 10.03 9.95 10.04 10.09
Resistance 1 (R1) 9.94 9.90 9.99 9.96 10.08
Pivot Point 9.83 9.83 9.85 9.84 9.83
Support 1 (S1) 9.74 9.75 9.79 9.76 9.64
Support 2 (S2) 9.63 9.70 9.64 9.63
Support 3 (S3) 9.54 9.63 9.61
Support 4 (S4) 9.56